FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4298422982> ?p ?o ?g. }

• W4298422982 endingPage "75" @default.
• W4298422982 startingPage "1" @default.
• W4298422982 abstract "Prostate cancer is very common and many localized tumours are non-aggressive. Determining which cancers are aggressive is important for choosing the most appropriate treatment (e.g., surgery, radiation, active surveillance). Current clinical risk stratification is reliable in forecasting the prognosis of groups of men with similar clinical and pathologic characteristics, but there is residual uncertainty at the individual level. The Prolaris cell cycle progression (CCP) test, a genomic test that estimates how fast tumour cells are proliferating, could potentially be used to improve the accuracy of individual risk assessment. This health technology assessment sought to determine the clinical utility, economic impact, and patients' perceptions of the value of the CCP test in low- and intermediate-risk localized prostate cancer.We conducted a systematic review of the clinical and economic evidence of the CCP test in low-and intermediate-risk, localized prostate cancer. Medical and health economic databases were searched from 2010 to June or July 2016. The critical appraisal of the clinical evidence included risk of bias and the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) Working Group criteria. We also analyzed the potential budget impact of adding the CCP test into current practice, from the perspective the Ontario Ministry of Health and Long-Term Care. Finally, we conducted qualitative interviews with men with prostate cancer, on the factors that influenced their treatment decision-making.For the review of clinical effectiveness, we screened 3,021 citations, and two before-after studies met our inclusion criteria. In one study, the results of the CCP test appeared to change the treatment plan (from initial to final plan) in 64.9% of cases overall (GRADE rating of the quality of evidence: Very low). In the other study, the CCP test changed the treatment received in nearly half of cases overall, compared with the initial plan (GRADE: Very low). No evidence was available on clinical outcomes of patients whose treatment was informed by CCP results. For the review of cost-effectiveness, 100 citations were identified and screened. No studies met the inclusion criteria. In our economic evaluation, we estimated that publicly funding the CCP test would result in a total net budget impact of $41.3 million in the first 5 years, mostly due to the cost of the CCP test. In our model, the relatively small cost savings ($7.3 million) due to treatment change (increased use of active surveillance and decreased use of interventional treatment) was not large enough to offset the high cost of the test. Patients viewed the test as potentially helpful but, due to the complexity of treatment decision-making, were unsure the test would ultimately change their treatment choices.We found no evidence to demonstrate the impact of the Prolaris CCP test on patient-important clinical outcomes. The limited evidence available shows that the test appears to provide information that, when considered in addition to clinical risk stratification, may change the treatment plan or actual treatment for some low- and intermediate-risk prostate cancer patients. As a result, there is insufficient data to inform the cost-effectiveness of the CCP test. Publicly funding the CCP test would result in a large incremental cost to the provincial budget." @default.
• W4298422982 created "2022-10-02" @default.
• W4298422982 date "2017-01-01" @default.
• W4298422982 modified "2023-10-18" @default.
• W4298422982 title "Prolaris Cell Cycle Progression Test for Localized Prostate Cancer: A Health Technology Assessment." @default.
• W4298422982 cites W1544025659 @default.
• W4298422982 cites W1603862075 @default.
• W4298422982 cites W1703961993 @default.
• W4298422982 cites W1759597685 @default.
• W4298422982 cites W1835664700 @default.
• W4298422982 cites W1875231889 @default.
• W4298422982 cites W1875720097 @default.
• W4298422982 cites W1887093532 @default.
• W4298422982 cites W1964206180 @default.
• W4298422982 cites W197485840 @default.
• W4298422982 cites W1975579343 @default.
• W4298422982 cites W1984011786 @default.
• W4298422982 cites W1988754534 @default.
• W4298422982 cites W1996587036 @default.
• W4298422982 cites W1999128767 @default.
• W4298422982 cites W2000056288 @default.
• W4298422982 cites W2003533845 @default.
• W4298422982 cites W2007872832 @default.
• W4298422982 cites W2009101549 @default.
• W4298422982 cites W2011225221 @default.
• W4298422982 cites W2012352122 @default.
• W4298422982 cites W2023468142 @default.
• W4298422982 cites W2024756496 @default.
• W4298422982 cites W2028643667 @default.
• W4298422982 cites W2034181056 @default.
• W4298422982 cites W2047677041 @default.
• W4298422982 cites W2049087175 @default.
• W4298422982 cites W2051710823 @default.
• W4298422982 cites W2071120462 @default.
• W4298422982 cites W2076826717 @default.
• W4298422982 cites W2087349778 @default.
• W4298422982 cites W2094359892 @default.
• W4298422982 cites W2095740768 @default.
• W4298422982 cites W2103444700 @default.
• W4298422982 cites W2103949891 @default.
• W4298422982 cites W2106869018 @default.
• W4298422982 cites W2116773250 @default.
• W4298422982 cites W2117792530 @default.
• W4298422982 cites W2129034112 @default.
• W4298422982 cites W2131357804 @default.
• W4298422982 cites W2131468967 @default.
• W4298422982 cites W2136403658 @default.
• W4298422982 cites W2142044692 @default.
• W4298422982 cites W2145626423 @default.
• W4298422982 cites W2152561234 @default.
• W4298422982 cites W2155987515 @default.
• W4298422982 cites W2156549595 @default.
• W4298422982 cites W2157996158 @default.
• W4298422982 cites W2158099560 @default.
• W4298422982 cites W2159972811 @default.
• W4298422982 cites W2160217483 @default.
• W4298422982 cites W2289280654 @default.
• W4298422982 cites W2299177375 @default.
• W4298422982 cites W2301685087 @default.
• W4298422982 cites W2341793082 @default.
• W4298422982 cites W2397834905 @default.
• W4298422982 cites W2409855773 @default.
• W4298422982 cites W2409858378 @default.
• W4298422982 cites W2417389079 @default.
• W4298422982 cites W2989886327 @default.
• W4298422982 cites W36939891 @default.
• W4298422982 cites W2064130501 @default.
• W4298422982 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28572867" @default.
• W4298422982 hasPublicationYear "2017" @default.
• W4298422982 type Work @default.
• W4298422982 citedByCount "9" @default.
• W4298422982 countsByYear W42984229822017 @default.
• W4298422982 countsByYear W42984229822019 @default.
• W4298422982 countsByYear W42984229822021 @default.
• W4298422982 countsByYear W42984229822022 @default.
• W4298422982 countsByYear W42984229822023 @default.
• W4298422982 crossrefType "journal-article" @default.
• W4298422982 hasConcept C121608353 @default.
• W4298422982 hasConcept C12174686 @default.
• W4298422982 hasConcept C126322002 @default.
• W4298422982 hasConcept C127413603 @default.
• W4298422982 hasConcept C142724271 @default.
• W4298422982 hasConcept C143998085 @default.
• W4298422982 hasConcept C147176958 @default.
• W4298422982 hasConcept C151730666 @default.
• W4298422982 hasConcept C152541439 @default.
• W4298422982 hasConcept C160735492 @default.
• W4298422982 hasConcept C162324750 @default.
• W4298422982 hasConcept C19527891 @default.
• W4298422982 hasConcept C204787440 @default.
• W4298422982 hasConcept C2777267654 @default.
• W4298422982 hasConcept C2777286243 @default.
• W4298422982 hasConcept C2780192828 @default.
• W4298422982 hasConcept C29456083 @default.
• W4298422982 hasConcept C38652104 @default.
• W4298422982 hasConcept C41008148 @default.
• W4298422982 hasConcept C50522688 @default.
• W4298422982 hasConcept C71924100 @default.

• next